433229-45-9

Upstream product

• 5398-77-6 para-methanesulfonylbenzaldehyde 
• 811806-90-3 1-(2-methoxyvinyl)-4-(methylsulfonyl)benzene 

Downstream Products

• 433230-27-4 (3-{(4R,5S)-2-Acetoxy-4-hydroxy-5-[(E)-(S)-3-hydroxy-4-(4-methanesulfonyl-phenyl)-but-1-enyl]-cyclopent-1-enylsulfanyl}-propylsulfanyl)-acetic acid methyl ester 

Relevant academic research and scientific papers

INHIBITORS OF THE MENIN-MLL INTERACTION

The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

CYCLIC TERTIARY AMINE COMPOUND

The present invention provides a cyclic tertiary amine compound which is capable of inhibiting the production of inflammatory cytokines. It is either a compound having a structure represented by the following general formula (I): (wherein A represents an optionally substituted trivalent group derived from pyrimidine, pyrrole, or the like; R1 represents an aryl or a heteroaryl group which may optionally be substituted; R2 represents a heteroaryl group which may optionally be substituted; and R3 represents a cyclic tertiary amino group) or a pharmacologically acceptable salt of the compound.